首页> 外文期刊>Nature >Data 'mishandling' stalls Down's syndrome test
【24h】

Data 'mishandling' stalls Down's syndrome test

机译:数据“处理不当”拖延唐氏综合症测试

获取原文
获取原文并翻译 | 示例
           

摘要

Research data supporting a non-invasive prenatal screen for Down's syndrome were "mishandled" and cannot be relied on, according to the biotechnology company that has been developing the test. rnOn 29 April Harry Stylli, chief executive of Sequenom in San Diego, California, said that four employees suspected of mishandling data had been suspended. An independent committee is investigating the matter. Investors have since filed several class-action lawsuits against the company. rnSequenom's tests rely on examining minute amounts of fetal DNA or RNA circulating in maternal blood. The hope is to provide an alternative to more invasive methods such as amniocentesis, which carry a small risk of miscarriage. The company intends to complete a new clinical validation of its assays by the end of the year, but will not file for regulatory approval until two larger clinical trials are completed in 2010.
机译:据正在开发该试验的生物技术公司称,支持唐氏综合症非侵入性产前筛查的研究数据“处理不当”,因此不能依靠。 rn 4月29日,加利福尼亚州圣地亚哥的Sequenom首席执行官Harry Stylli说,四名涉嫌处理数据不当的员工已被停职。一个独立的委员会正在调查此事。此后,投资者已对该公司提起了几项集体诉讼。 rn Sequenom的测试依靠检查母体血液中微量的胎儿DNA或RNA。希望为羊膜穿刺术等侵入性较小的流产风险提供替代方法。该公司计划在今年年底之前完成对其测定的新临床验证,但是直到2010年完成两项较大的临床试验后,该公司才会申请监管部门的批准。

著录项

  • 来源
    《Nature》 |2009年第7243期|23-23|共1页
  • 作者

  • 作者单位
  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号